Oral octreotide efficacy maintained in more than 90% of adul
More than 90% of participants with acromegaly in the EMPOWERED phase 3 trial were responders to oral octreotide at 36 weeks. There were 60 participants who continued to use oral octreotide in an open-label extension. Participants were defined as responders if they had an insulin-like growth factor I less than 1.3 times the upper limit of normal. Safety outcomes were collected at the end of each year. On average, those 19 patients actually showed improved outcomes in terms of their acromegaly symptom control as well as how they regarded their oral octreotide treatment’s convenience and their overall satisfaction with the oral octreotide.

Source: https://www.healio.com/news/endocrinology/20220620/oral-octreotide-efficacy-maintained-in-more-than-90-of-adults-with-acromegaly-at-3-years